Category: Startup News

Sophiris Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights

From Startup Sophiris Bio Link to Full Article: http://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-reports-third-quarter-2018-financial-results-and SAN DIEGO and VANCOUVER, British Columbia, Nov. 13, 2018 /PRNewswire/ — Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases,

Aptinyx Reports Third Quarter 2018 Financial Results and Business Highlights

From Startup Aptinyx Link to Full Article: https://ir.aptinyx.com/news-releases/news-release-details/aptinyx-reports-third-quarter-2018-financial-results-and Completed enrollment in Phase 2 study of NYX-2925, top-line data anticipated in the first half of 1Q 2019 Reported demonstration of NYX-2925 pharmacodynamic activity in humans Plan to announce data from interim analysis of exploratory fibromyalgia study in December 2018 EVANSTON, Ill.,

Sigilon Therapeutics Announces Appointment of Four New Members of Senior Management Team

From Startup Sigilon Therapeutics Link to Full Article: http://sigilon.com/2018/11/13/sigilon-therapeutics-announces-appointment-of-four-new-members-of-senior-management-team/ CAMBRIDGE, Mass. — Nov. 13, 2018 — Sigilon Therapeutics, a biopharmaceutical company creating functional cures for chronic diseases using Shielded Living Therapeutics, today announced the appointment of four new members of its senior management team as the company prepares to advance its

Urovant Sciences Reports Financial Results for the Second Fiscal Quarter Ended September 30, 2018 and Provides Corporate Update

From Startup Urovant Link to Full Article: https://urovant.com/2018/11/12/urovant-sciences-reports-financial-results-for-the-second-fiscal-quarter-ended-september-30-2018-and-provides-corporate-update/ BASEL, Switzerland & IRVINE, Calif.–(BUSINESS WIRE)–Nov. 12, 2018– Urovant Sciences Ltd. (Nasdaq: UROV),a clinical-stage biopharmaceutical company focused on developing therapies for urologic conditions, today reported financial results for the three and six months ended September 30, 2018 and announced corporate updates. Recent Business Highlights Completed enrollment in international

U.S. Surgeon General Jerome Adams Discusses Opioid Alternatives and the Importance of Partnerships at Heron Therapeutics

From Startup Heron Therapeutics Link to Full Article: https://herontherapeutics.gcs-web.com/news-releases/news-release-details/us-surgeon-general-jerome-adams-discusses-opioid-alternatives SAN DIEGO, Nov. 12, 2018 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today hosted a fireside

Aptinyx Exploratory Clinical Studies Provide First Evidence that NYX-2925 Elicits Rapid, Persistent, NMDAr-Mediated Pharmacodynamic Activity in Humans

From Startup Aptinyx Link to Full Article: https://ir.aptinyx.com/news-releases/news-release-details/aptinyx-exploratory-clinical-studies-provide-first-evidence-nyx Studies in Healthy Human Volunteers Reinforce Mechanism of Action Observed in Preclinical Studies EVANSTON, Ill., Nov. 12, 2018 (GLOBE NEWSWIRE) — Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced

Eidos Therapeutics Announces Positive Phase 2 Data for AG10 in Symptomatic Patients with Mutant or Wild-Type TTR Amyloid Cardiomyopathy

From Startup Eidos Therapeutics Link to Full Article: http://ir.eidostx.com/news-releases/news-release-details/eidos-therapeutics-announces-positive-phase-2-data-ag10 AG10 Was Well Tolerated in Subjects Administered 400 mg or 800 mg Twice Daily for 28 Days AG10 Resulted in Average TTR Stabilization Greater than 90% in All Actively Treated Subjects at Day 28 AG10 Significantly Raised Serum TTR Concentrations (p90%